Literature DB >> 24419526

NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT.

K M Williams1, O Hnatiuk2, S A Mitchell3, K Baird4, S M Gadalla5, S M Steinberg6, J Shelhamer7, A Carpenter8, D Avila8, T Taylor8, L Grkovic9, D Pulanic9, L E Comis10, B Blacklock-Schuver8, R E Gress8, S Z Pavletic8.   

Abstract

Bronchiolitis obliterans syndrome (BOS) is a serious complication of chronic GVHD (cGVHD) following HSCT (hematopoietic SCT). The clinical diagnosis of BOS is based on pulmonary function test (PFT) abnormalities including: FEV1<75% predicted and obstructive FEV1/VC ratio, calculated using reference equations. We sought to determine if the frequency of clinical diagnoses and severity of BOS would be altered by using the recommended NHANES III vs older equations (Morris/Goldman/Bates, MGB) in 166 cGVHD patients, median age 48 (range: 12-67). We found that NHANES III equations significantly increased the prevalence of BOS, with an additional 11% (18/166) meeting diagnostic criteria by revealing low FEV1 (<75%) (P<0.0001), and six additional patients by obstructive ratio (vs MBG). Collectively, this led to an increase of BOS incidence from 17 (29/166) to 29% (41/166). For patients with severe BOS, (FEV1<35%), NHANES III equations correctly predicted death 71.4% vs 50% using MGB. In conclusion, the use of NHANES III equations markedly increases the proportion of cases meeting diagnostic criteria for BOS and improves prediction of survival.

Entities:  

Mesh:

Year:  2014        PMID: 24419526      PMCID: PMC5562366          DOI: 10.1038/bmt.2013.222

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  37 in total

1.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation.

Authors:  J Douglas Rizzo; John R Wingard; Andre Tichelli; Stephanie J Lee; Maria Teresa Van Lint; Linda J Burns; Stella M Davies; James L M Ferrara; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

2.  Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%.

Authors:  James E Hansen; Xing-Guo Sun; Karlman Wasserman
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT.

Authors:  A Gassas; H Craig-Barnes; S Dell; J Doyle; T Schechter; L Sung; M Egeler; N Palaniyar
Journal:  Bone Marrow Transplant       Date:  2012-11-19       Impact factor: 5.483

Review 5.  Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature.

Authors:  S Kumar; A Tefferi
Journal:  Ann Hematol       Date:  2001-07       Impact factor: 3.673

6.  Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study.

Authors:  D C L Lam; B Lam; M K Y Wong; C Lu; W Y Au; E W C Tse; A Y H Leung; Y L Kwong; R H S Liang; W K Lam; M S M Ip; A K W Lie
Journal:  Bone Marrow Transplant       Date:  2011-02-14       Impact factor: 5.483

7.  Discordance in spirometric interpretations using three commonly used reference equations vs national health and nutrition examination study III.

Authors:  Jacob Collen; David Greenburg; Aaron Holley; Christopher S King; Oleh Hnatiuk
Journal:  Chest       Date:  2008-11       Impact factor: 9.410

8.  Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth; Todd E DeFor; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

9.  Autologous blood pleurodesis for pneumothorax complicating graft-versus-host disease-related bronchiolitis obliterans.

Authors:  C Chadwick; S M Marven; A J Vora
Journal:  Bone Marrow Transplant       Date:  2004-02       Impact factor: 5.483

10.  Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force.

Authors:  R F Duarte; H Greinix; B Rabin; S A Mitchell; G Basak; D Wolff; J A Madrigal; S Z Pavletic; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-08-19       Impact factor: 5.483

View more
  3 in total

Review 1.  How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

2.  Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis.

Authors:  Kirsten M Williams; Steven Z Pavletic; Stephanie J Lee; Paul J Martin; Don E Farthing; Frances T Hakim; Jeremy Rose; Beryl L Manning-Geist; Juan C Gea-Banacloche; Leora E Comis; Edward W Cowen; David G Justus; Kristin Baird; Guang-Shing Cheng; Daniele Avila; Seth M Steinberg; Sandra A Mitchell; Ronald E Gress
Journal:  Transplant Cell Ther       Date:  2022-02-01

3.  MSC therapy attenuates obliterative bronchiolitis after murine bone marrow transplant.

Authors:  Kashif Raza; Trevor Larsen; Nath Samaratunga; Andrew P Price; Carolyn Meyer; Amy Matson; Michael J Ehrhardt; Samuel Fogas; Jakub Tolar; Marshall I Hertz; Angela Panoskaltsis-Mortari
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.